United Therapeutics Corporation
UTHR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $2 | $2 |
| % Growth | 23.6% | 20.2% | 14.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $3 | $2 | $2 | $2 |
| % Margin | 89.2% | 88.9% | 92.4% | 92.7% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $1 | $1 | $1 | $1 |
| % Margin | 47.9% | 50.9% | 50.6% | 33% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | $2 | $1 | $1 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1 | $1 | $1 | $0 |
| % Margin | 41.5% | 42.3% | 37.6% | 28.2% |
| EPS | 26.44 | 21.04 | 15.98 | 10.6 |
| % Growth | 25.7% | 31.7% | 50.8% | – |
| EPS Diluted | 24.64 | 19.81 | 15 | 10.06 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $2 | $1 | $1 | $1 |
| % Margin | 57.5% | 59.6% | 53.7% | 43.7% |